Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000929638-25-000784·Prelude Therapeutics Inc
Schedule 13G ownership disclosure
Prelude Therapeutics, Inc.
Common Stock, par value $0.0001 per share · CUSIP: 74065P101
Event date: 2024-12-31
- Filing-level shares
- 5,489,130
- Percent of class
- 9.5%
- Vaddi Krishna
Shares: 5,489,130 · Class: 9.5%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000929638-25-000784
- Form type
- SCHEDULE 13G/A
- Filer
- Prelude Therapeutics Inc
- CIK
- CIK 1678660
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership